EDWARDS LIFESCIENCES overview

CLASP IID ONE-YEAR DATA CONFIRM SAFETY AND EFFICACY OF EDWARDS PASCAL SYSTEM FOR DEGENERATIVE MITRAL REGURGITATION PR Newswire SAN FRANCISCO, Oct. 26, 2023 SAN FRANCISCO , Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two contemporary mitral transcatheter edge-to-edge repair (TEER) therapies, as well as one-year results from the CLASP IID registry. The studies...

TRISCEND II SIX-MONTH DATA FOR FIRST 150 PATIENTS SUCCESSFULLY DEMONSTRATE SAFETY AND EFFICACY OF EDWARDS EVOQUE SYSTEM FOR SEVERE TRICUSPID REGURGITATION PR Newswire SAN FRANCISCO, Oct. 26, 2023 SAN FRANCISCO , Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced successful results from TRISCEND II, a randomized controlled pivotal trial designed to evaluate the safety and effectiveness of the groundbreaking EVOQUE tricuspid valve replacement system with...

EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS PR Newswire IRVINE, Calif., Oct. 25, 2023 IRVINE, Calif. , Oct. 25, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Sept. 30, 2023. Recent Highlights and Outlook Q3 sales grew 12 percent to $1.48 billion ; constant currency 1 sales grew 11 percent Q3 TAVR sales grew 11 percent; constant currency sales grew 10 percent Q3 EPS of $0.63 ; adjusted 1 EPS of $0.59 Received CE Mark for EVOQUE,...

FIVE-YEAR DATA FROM PARTNER 3 TRIAL DEMONSTRATE EXCELLENT SURVIVAL FOR PATIENTS RECEIVING EDWARDS SAPIEN 3 VALVE PR Newswire SAN FRANCISCO, Oct. 24, 2023 SAN FRANCISCO , Oct. 24, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced new data from the PARTNER 3 trial demonstrating continued low rates of all-cause mortality, disabling stroke and rehospitalization at five years. These data, which represent the longest clinical follow-up for a low surgical risk cohort of transcatheter...

EDWARDS EVOQUE TRANSCATHETER TRICUSPID VALVE REPLACEMENT SYSTEM RECEIVES CE MARK PR Newswire IRVINE, Calif., Oct. 19, 2023 IRVINE, Calif. , Oct. 19, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced the company's EVOQUE tricuspid valve replacement system received CE Mark for the transcatheter treatment of eligible patients with tricuspid regurgitation (TR). The EVOQUE system is the world's first transcatheter valve replacement therapy to receive regulatory approval...

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON OCTOBER 25, 2023 PR Newswire IRVINE, Calif., Oct. 18, 2023 IRVINE, Calif. , Oct. 18, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2023 after the market closes on Wednesday, October 25, 2023 , and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The...

BetterInvesting™ Magazine Update on Edwards Lifesciences Corp. and 3M Company PR Newswire TROY, Mich., Aug. 29, 2023 TROY, Mich. , Aug. 29, 2023 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Edwards Lifesciences Corp. (NYSE:EW) as its "Stock to Study" and 3M Company (NYSE:MMM) as its "Undervalued Stock" in the November 2023 issue for investors' informational and educational use. "Too many novice investors still don't realize...